The announcement of rewarding shareholders with founding shares and a royalty coupon, especially with a condition that discourages short selling, is likely to be viewed positively by the market. It could lead to increased shareholder loyalty and potentially stabilize or increase the stock price in the short term, assuming board approval is granted. The plan to have ketamine supplies ready by July 2024 also indicates progress in product development, which could further bolster investor confidence.